ACTO Receives Prestigious Veeva Gold Product Partner Recognition After Years of Collaborative Success

Celebrating a Milestone: ACTO Achieves Veeva Gold Product Partner Status

Recently, ACTO, a company committed to integrating human intelligence with AI in the Life Sciences sector, proudly announced that it has attained Veeva Gold Product Partner status. This significant recognition comes after nearly ten years of fruitful collaboration with Veeva, a key player in providing cloud-based solutions for the Life Sciences industry.

ACTO’s journey with Veeva began in 2017 when it first joined the Veeva Product Partner Program. Over the years, ACTO has consistently demonstrated its dedication to enhancing customer engagement and improving outcomes for field teams within the pharmaceutical and biotechnology markets. By achieving Veeva Silver Product Partner status in 2021 and later Veeva AI Partner status in 2024, ACTO has showcased its commitment to continuous improvement and innovation.

The Power of Partnership

The Veeva Gold Product Partner status reflects ACTO’s expertise in integrating its technology with various Veeva products, particularly Veeva PromoMats, Veeva MedComms, and Veeva Vault CRM. This collaboration aims to improve the effectiveness of field teams by providing access to approved content and real-time operational insights, bolstering their confidence and capacity to engage healthcare professionals accurately.

Parth Khanna, CEO of ACTO, emphasized the importance of maintaining alignment with the latest approved content in order to optimize interactions with healthcare professionals. He noted that their partnership with Veeva has allowed for seamless integration of ACTO’s platform with the daily operational systems used by customers, facilitating a more efficient and compliant engagement strategy.

Innovative Solutions for Life Sciences

ACTO’s suite of solutions is designed to enhance performance and learning for customer-facing professionals. One notable offering is CxZone, an AI-simulated role-playing tool that allows sales representatives to practice conversations utilizing the latest approved messaging from PromoMats. Likewise, Medical Science Liaisons (MSLs) benefit from practicing scientific exchanges using medical content from MedComms, ensuring they are well-prepared for interactions with healthcare providers.

Additionally, the ACTO Talk TRx™ tool grants access to current and approved resources housed within PromoMats and MedComms, incorporating essential talking points and strategies for effective healthcare interactions.

Kristn Peck, Vice President of Alliances at Veeva, acknowledged ACTO’s ongoing contributions to enhancing field readiness and operational efficiency through their ever-expanding, validated solutions. She praised ACTO for its commitment to delivering integrated solutions tailored for the Life Sciences industry.

Looking Ahead

The partnership between ACTO and Veeva is set to further evolve as they continue to work together to leverage technology for improving field team effectiveness and customer engagement. Companies within the Life Sciences ecosystem are invited to connect with ACTO to explore how these innovative solutions can elevate their operational strategies.

As this collaboration progresses, ACTO is set to showcase its advancements at the upcoming Fierce PharmaWeek in Philadelphia from September 14 to 17. Attendees can learn more about ACTO’s offerings and how they're reshaping customer engagement in the Life Sciences sector.

About ACTO

ACTO is trusted by 14 of the top 50 pharmaceutical companies and various rising biotech and medtech organizations. By combining human intelligence with empathetic AI, ACTO aims to transform how therapies reach patients post-regulatory approval. The company's platform is rooted in the highest regulatory standards, being FDA 21 CFR Part 11 validated and SOC 2 Type II certified.

For more information about ACTO and its innovative solutions, please visit www.acto.com or follow them on LinkedIn for the latest updates.